What The Study Did: In this study, short-term effectiveness of the first dose of the BNT162b2 (BioNTech/Pfizer) vaccine against SARS-CoV-2 infection 13 to 24 days after immunization in a real-world setting was assessed.
Authors: Gabriel Chodick, Ph.D., of the Maccabi Institute for Research & Innovation, Maccabi Healthcare Services, in Tel Aviv, Israel, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https:/
(doi:10.1001/jamanetworkopen.2021.15985)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
###
Media advisory: The full study is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.
About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
Media Contact
JAMA Network Media Relations
mediarelations@jamanetwork.org